Clinical Trial

DP303c in Patients With HER2-positive Advanced Breast Cancer

Name: DP303c in Patients With HER2-positive Advanced Breast Cancer — clinical trial record (NCT05901935)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Record status

This record was last updated June 13, 2023 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.

Summary

This is a study of DP303c in patients with HER2-positive advanced breast cancer.

Trial Details

NCT Number	NCT05901935
Lead Sponsor	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions	HER2-positive Advanced Breast Cancer
Enrollment	420 participants
Start Date	2023-07
Primary Completion	2026-01 (estimated)
Study Completion	2028-07 (estimated)
Updated on ClinicalTrials.gov	2023-06-13